Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones

Details Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones

2008-03-25

2008-03-25

Berch, Mark L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S279000

Reexamination Certificate

active

10987656

ABSTRACT:
Compounds of the Formula:where X1, Ar1, R1, and R2are as defined herein, and compositions comprising the same. Also provided are methods for using compounds of Formula I in treating p38 mediated disorders in a patient.

REFERENCES:
patent: 4215216 (1980-07-01), Scotese et al.
patent: 5037826 (1991-08-01), Blythin et al.
patent: 5620981 (1997-04-01), Blankley et al.
patent: 5733913 (1998-03-01), Blankley et al.
patent: 5733914 (1998-03-01), Blankley et al.
patent: 5945422 (1999-08-01), Doherty et al.
patent: 6518276 (2003-02-01), Arzeno et al.
patent: 6696566 (2004-02-01), Chen et al.
patent: 6936612 (2005-08-01), Barvian et al.
patent: 2003/0073668 (2003-04-01), Booth et al.
patent: 2003/0149001 (2003-08-01), Barvian et al.
patent: 0 278 686 (1988-08-01), None
patent: 0 790 997 (2000-03-01), None
patent: WO93/17682 (1993-09-01), None
patent: WO96-34867 (1996-11-01), None
patent: WO98/33798 (1998-08-01), None
patent: WO99/61444 (1999-12-01), None
patent: WO 01/55148 (2001-08-01), None
patent: WO 01/70741 (2001-09-01), None
patent: WO0264594 (2002-02-01), None
patent: WO03062236 (2003-01-01), None
Lee, et al., “p38 Mitogen-Activated Protein Kinase Inhibitors—Mechanisms and Therapeutic Potentials,” Pharmacol. Ther., May-Jun. 1999; 82(2-3): 389-97.
Hashimoto, et al. “Selective Inhibitor of p38 Mitogen-Activated Protein Kinase Inhibits Lipopolysaccharide-Induced Interleukin-8 Expression in Human Pulmonary Vascular Endothelial Cells,” Journal of Pharmacology and Experimental Therapeutics, vol. 293, No. 2, pp. 370-375, 2000.
Hensley, et al. “p38 Kinase Is Activated in the Alzheimer's Disease Brain,” Journal of Neurochemistry, Vol. No. 5, 1999, pp. 2053-2058.
Johnson, et al. “Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases,” Science, vol. 298, Dec. 6, 2002, 1911-1912.
Blease “Targeting Kinases in Asthma,” Expert Opin. Investig. Drugs, 2005, vol. 14, No. 10, 1213-1220.
Boschelli, et al, “Synthesis and Tyrosine Kinase Inhibitory Activity of a Series of 2-Amino-8H-pyrido[2,3-d]pyrimidines. Identification of Potent, Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitors,”Journal of Med. Chem., (1998), pp. 4365-4377, vol. 41.
Klutchko, et al., “2-Substituted Aminopyrido[2,3-d] pyrimidin-7(8H)-ones. Structure-Activity Relationships Against Selected Tyrosine Kinases and in Vitro and in Vivo Anticancer Activity,”Journal of Med. Chem., (1998), pp. 3276-3292, vol. 41.
Barvian, et al., “Pyrido[2,3-d]pyrimidin-7-one Inhibitors of Cyclin-Dependent Kinases,”Journal of Med. Chem., (2000), pp. 4606-4616, vol. 43.
Hamby, et al., “Structure-Activity Relationships for a Novel Series of Pyrido[2,3-d]pyrimidine Tyrosine Kinase Inhibitors,”Journal Med. Chem., (1997), pp. 2296-2303, vol. 40.
Edwards, et al., “Osmotic stress induces both secretion and apoptosis in rat alveolar type ii cells,”APStracts5:0150L, Jun. 16, 1998.
Munoz et al., “Causes of Alzheimer's Disease,”CMAJ(Canadian Medical Assoc.), (2000), pp. 65-72, vol. 162(1).
Palmer, “Pharmacotherapy for Alzheimer's disease: progress and prospects,”TRENDS in Pharmacological Sciences, Sep. 2002, pp. 426-433, vol. 23(9).
Boehm et al.,Expert Opinion on Therapeutic Patents, “New inhibitors of p38 kinase,” (2000), pp. 25-37, vol. 10(1), Ashley Publications Ltd., ISSN 1354-3776.
Dalrymple et al., “p38 Mitogen Activated Protein Kinase as a Therapeutic Target for Alzheimer's Disease,”J. Molecular Neuroscience, (2000), vol. 19, pp. 295-299.
Haddad et al., “Role of P38Map Kinase in LPS-Induced Airway Inflammation in the Rat,”Brit. J. Pharmacology, (2001), pp. 1715-1724, vol. 132(8).
Underwood et al., “SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung,”Am. J. Physiol. Lung Cell Mol. Physiol., (2000), pp. L895-L902, vol. 279.
Lee et al., “Review, Inhibition of p38MAP Kinase as a therapeutic strategy”,Immunopharmacology, (2000), pp. 185-201, vol. 47.

Affiliated with

Also associated with

Rating

Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3913687